"The LLS pediatric research funding is crucial to helping us find better treatment options for still incurable forms of pediatric leukemias and other blood cell cancers. The form of cancer that we study carries a chromosomal abnormality called a KMT2A gene translocation that is associated with a very poor prognosis, and primarily afflicts infants and young children. Not only do these patients respond poorly to the conventional chemotherapy typically used for treatment, but also they are particularly susceptible to immediate life threatening and more long-term complications of the treatment. What our TRP grant is allowing us to do is answer some very precise mechanistic questions in regards to the interaction of two different drugs and how these drugs can be used for clinical benefit as anti-leukemia treatment in this ultra-high-risk patient population. Without the emphasis of LLS on these forms of leukemia and support of LLS, we would not be able be moving forward with this research as we now are doing."

"Support from The Leukemia & Lymphoma Society has been impactful in my research for many years, and I am very grateful to LLS. This most recent grant will help us advance a potentially novel immunotherapeutic approach for the treatment of myeloid leukemias, which would not be able to move as quickly without the generous funding from LLS."

"I am very honored to receive this award from The Leukemia & Lymphoma Society. These funds will support the development of allogeneic “off-the-shelf” T-cell therapies that will resist rapid immune rejection by the host and thus result in more potent and durable activity in patients with blood cancers. The award will greatly facilitate optimization and translation of this technology to the clinic.""

Coming Soon!

"My research laboratory and collaborators are truly honored to receive the prestigious LLS TRP Award. Research on the BCL-2 antagonist venetoclax has shown promising efficacy to improve outcomes of t(11;14)-expressing multiple myeloma patients and merits further exploration. Towards that end, this funding enables us to validate functional mitochondrial biomarkers and test combinations of mitochondrial targeting agents to induce sensitivity to venetoclax. We believe interrogating mitochondrial function for the expanded application of this potent BH3 mimetic holds answers to key questions in multiple myeloma, and we're excited to push forward."